Interim report
Page 1
Ref: Akums/Exchange/2025-26/78 February 13, 2026 To, The Listing Department National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 Symbol: AKUMS To, The Listing Department BSE Limited Rotunda Building, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001 Scrip Code: 544222 Sub: Outcome of Board Meeting held on 13th February, 2026 Respected Sir/ Madam, In terms of Regulation 30 and 33 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform that the Board of Directors of the Company in its meeting held today i.e. 13th February, 2026 has inter-alia considered and approved the following: 1. The Un-audited (Standalone & Consolidated) Financial Results for the quarter and nine months ended 31st December, 2025, along with the Limited Review Reports thereon, as received from the Statutory Auditors, Walker Chandiok & Co. LLP, Chartered Accountants. Copies of such Integrated financial results along with the Limited Review Reports thereon are enclosed herewith as Annexure-A. The Board Meeting commenced at 02:20 PM and concluded at 3:31 PM. This is for your kind information and record. Thanking You For Akums Drugs and Pharmaceuticals Limited Dharamvir Malik Company Secretary & Compliance Officer Encl: as above
Page 2
t Annexue - A’ Walker Chandiok & Co LLP Walker Chandiok & Co LLP L 41, Connaught Circus, Outer Circle, New Delhi — 110 001 India T +91 11 45002219 F +91 11 42787071 Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) To the Board of Directors of Akums Drugs and Pharmaceuticals Limited 1. We have reviewed the accompanying statement of standalone unaudited financial results (‘the Statement’) of Akums Drugs and Pharmaceuticals Limited (‘the Company’) for the quarter ended 31 December 2025 and the year to date results for the period 01 April 2025 to 31 December 2025, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (‘Listing Regulations’). 2. The Statement, which is the responsibility of the Company’s management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (‘Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 (‘the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. Walker Chandiok & Co LLP is registered with kmited liabity vith identfication Offces v Ahmedsbad Bengaur Crarisgam Crernas Defvacun Goa Guragram Hyserabad ke Koo okata Mamba number AAC-2085 and has ts registered New Dety Noda 3 Pure office ai L41. Connaught Circus. Outer Circle. Nev Delh 110001, India
Page 3
Walker Chandiok & Co LLP Independent Auditor’s Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont’d) 4. Based on our review conducted as above and the consideration of the review reports of the other auditor on separate interim financial information of Akums Employee Benefit Trust (“the Trust") as referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. 5. We draw attention to note 5 to the accompanying Statement relating to a search and seizure operation carried out by the Income Tax Department during the financial year ended 31 March 2025 at certain offices and manufacturing units of the Company and its subsidiaries, and the residences of selected key managerial personnel of the Company from 15 January 2025 to 21 January 2025 under Section 132 of the Income Tax Act, 1961. During the previous quarter, the Company had received notice under Section 158BC of the Income tax Act, 1961, whereby the Company has complied with notices by furnishing returns with no undisclosed income for the relevant block period from 01 April 2018 to 12 March 2025. Further, in the current quarter, the Company have received notice under Section 142(1)/143(2) of the Income Tax Act, 1961 to furnish information for the aforesaid block period. The Company is in the process of responding to the said notices and submitting the required documents to the Income Tax Department. Pending conclusion of the ongoing search and seizure proceedings, the impact of this matter on the standalone financial results for the quarter and nine months period ended 31 December 2025 and the adjustments (if any) required is presently not ascertainable. Our conclusion is not modified in respect of this matter. 6. We did not review the interim financial information of the Trust included in the Statement, where such interim financial information reflects total revenues of nil and Z nil, total net loss after tax of T 0.00 million and % 0.00 million, and total comprehensive loss of ¥ 0.00 million and 0.00 million, for the quarter and year to date period ended on 31 December 2025, respectively, as considered in the Statement. The statement also includes the Company’s share in the net profit (including other comprehensive income) of % 20.75 million and ¥ 39.57 million for the quarter and year to date period ended on 31 December 2025, respectively, in respect of a Limited Liability Partnership (LLP), whose interim financial information have not been reviewed by us. The interim financial information of the Trust and LLP have been reviewed by the other auditor, whose reports have been furnished to us by the management, and our conclusion, in so far as it relates to the amounts and disclosures included in respect of the Trust and LLP, is based solely on the review reports of such other auditor.
Page 4
Walker Chandiok & Co LLP Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont'd) Further, the aforementioned interim financial information of this Trust has been prepared in conformity with the Accounting Standards specified under section 133 of the Act, read with the Companies (Accounting Standards) Rules, 2021. The Company’s management has converted the interim financial information of this Trust in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015 as applicable to the Company. We have reviewed these conversion adjustments made by the Company’s management. Our conclusion on the Statement is not modified in respect of the above matter with respect to our reliance on the work done by and the reports of the other auditor. For Walker Chandiok & Co LLP Chartered Accountants Firm Registration No: 001076N/N500013 ~lowu Tarun Gupta Partner Membership No. 507892 UDIN: 26507842 NP KND $5i0 Place: New Delhi Date: 13 February 2026
Page 5
Akums Drugs and Pharmaceuticals Limited Regd. Office: 304, Mohan Place, LSC, C-Block, Saraswati Vihar, Delhi-110034 el : L24239DL2004PLC125688 Email 1d: cs@akums.net; Website: www.akums.in Statement of unaudited standalone financial results for the quarter and nine months period ended 31 December 2025 (% in million, unless otherwise stated) Quarter ended Nine months period ended | Year ended o Warkitaihcs 31 December | 30 September | 31 December | 31 December | 31 December |31 March 2025, 2025 205 2024 2025 204 Unaudited Unaudited | Unaudited | Unaudited | Unaudited Audited 1 [income Revenue from operations 3.686.06 300315 337407 10,103.64 983031 1311784 Other income 296.04 27077 33842 5236 92142 124192 Total income (1) 3.952.10 3.363.92 371249 10956.00 1075173 14359.76 T [Expenses Cost of materials consumed 2,023.10 2,066.24 617533 6,039.95 8.110.58 Changes in inventories of finished goods and work-in-progress. (11097 78.54 2887 (103.99) (100.50) Employee benefits expense 545.77 50340 160115 1479.00 2017.36 Finance costs 2077 294 7445 153.09 [Depreciation and amortisation expense 106.90 106,83 33082 39545 Fair value changes to financial instruments - - - - (38.67) (Other expenses 54753 46634 38563 144156 1,744.08 Total expenses (I1) 358535 305191 3.063.58 9652.18 904391 1228139 L [Profit before exceptional items and tax (I-11) 396.75| 31201 548.91 130382 2,078.37] IV [Exceptional items (refer note 6) 38.08 - - 38.08 - v |Profit before tax for the period/ year (III-IV) 35867 51201 54891 126574 207837 VI |Tax expense Current tax for current period! year 99.01 83.13 BLI7 34527 41013 49274 for earler years (1392) - 0.60) 13.92) 390 390 Deferred tax (credity/ charge for current period year (1530 574) 6.66 (36.97)] (.19) for carlier years 693 - = 693 eLIb)| Total tax expense 7753 77.39 137.23 30131 468.39 VIL [Profit for the period/ year (V-VI) 28114 23462 41168 96443 133409 1,609.98 VI [Other comprehensive income ttems that will not be rechassified o statement of profit and loss Re-measurement gains/(losses) on defined benefit plans 352 21.30) 257 (.50) (©.19) (0.96) Tax effect relating to these items (©0.96) 536 (0.69)] 121 005 024 Other comprehensive income, net of tax 286 (15.94) 193 659) ©19) ©.72) IX |Total comprehensive income for the period/ year (VIFVIII) (comprising profit 28400 218.68 361 960.84 133395 1,609.26 for the period year and other comprehensive income, net of tax) X |Paid-up share capital (net off shares held by ESOF trust) (refer note 8) 306.21 306.21 30621 30621 30621 30621 X1 [Other equity 22.746.26 X [Eaming per share (EPS) (face value of 2 2/~ each) (in 2)* [Basic and diluted 184 153 269 630 8.99 1076 #EPS for the quarters and nine months period have not been annualised
Page 6
Notes: Place: Date: ‘The above standalone financial results have been reviewed by the Audit Comumittee and thereafter approved by the Board of Directors at their meetings held on 13 February 2026. These standalone financial results for quarter and nine months period ended 31 December 2025 have been subjected to limited review by the statutory auditors of the Company. The limited review report does not contain any qualifications. These standalone financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended and prescribed under Section 133 of the Companics Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (a5 amended). The Company had completed its Initial Public Offer (IPO) of 27,368,143 equity shares of face value of 2 2 each at an issue price of 2 679 per shar (including sharc premium of 2 677 per sharc). A discount of ¥ 64 per share was offercd to cligible employees biding in the employee reservation portion of 243,826 equity shares. Pursuant to IPO, the cquity shares of the Company wwere listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on 6 August 2024. The issue comprised of fresh issue of 10,037,708 equity sharcs agaregating to 2 6,800.00 million and offer for sale of 17,330,435 cquity shares by selling shareholders, aggregating to 2 11,767.37 million 1PO related expenses were carlier estimated at 2 1,116.58 million and were allocated between the Company and the selling shareholders in proportion to their respective shares in the issue. Subsequent to quarter ended 31 December 2025, the Company has assessed the actual 1PO expenses amounted 1o 2 990,61 million as against the carlicr estimated expenscs of ¥ 1,116.58 million as disclosed in the Prospectus, resulting in an cxcess provision of 2 125.98 million. The IPO expenses were initially withheld from the IPO proceeds and were allocatcd between the Company and the sclling sharcholders i proportion to their respective shares in the issue. Accordingly, the excess amount of ¥ 125,98 million is being released proportionately to the Comps and the selling sharcholders. Out of the aforcsaid cxcess amount, ¥ 48.10 million attributable (o the Company i to be reallcated towards the objects of the issue as decided by the Board. The balance amount attributable to the selling sharcholders will be released to them in proportion to their respective entitlements. The wrilisation of the net IPO proceeds, prior to aforementioned reallocation, is summarised below: Objects Planned net | Actual net | Utilisation upto] Unufilised proceedsasper | proceeds | 31 December | amount as on prospectus 205 31 December Repayment/prepayment of all or certain borrowings of the Company 159910 1,599.10 1,599.10 - [Repayment/prepayment of all or certain borrowings of the subsidiarics namely,| 227090 227090 227090 B [Maxcure Nutravedics Limited and Pure and Cure Healtheare Private Limited Funding incremental working capital requirements of the Company. 55000 550,00 550.00 - Pursuing inorganic growth iniiatives through acquisitions 278.70 278.70 7870 E [General corporate purposes 167500 1.675.00 1.675.00 - [Total proceeds (net of IPO expenses) 637370 637370 637370 - “The Company operates in anly one segmnent which is "Pharmaceuticals’ Therefore, disclosure relating to scgment is not applicable and accordingly not made During the financial year ended 31 March 2025, from 15 January 2025 to 21 January 2025, the Income Tax Department ("IT Department") has conducted a scarch and scizure operation under Section 132 of the Income Tax Act, 1961, at certain offices and manufacturing units of the Company and its subsidiaries, and the residences of selected key managerial personnel of the Company and its subsidiarics. During the scarch and scizur proceedings, the Company has fully cooperted, provided the required information and responses to the IT Department. As a part of scarch and scizure opcration, the IT Department has cloned clectronic books of accounts, laptops, data backups and seized certain documents, cash and other materials for further invastigation. The business and aperations of the Company continucd without any disruptions, except some minor operational hiccups, and customer commitments were met during this period. During the previous quarte, the Company has reccived notice under Section 158BC of the Income tax Act, 1961, which requires the Company, in consequence of aforesaid search and seizurc operations initiated under Section 132, to furnish returns of undisclosed income for the relevant block period from 01 April 2018 to 12 March 2025 in the prescribed form and manner as per rule 12AE of Incoms-tax Rulcs, 1962 setting forth such other particulars as may be prescribed by the Income-tax Act, 1961 within 60 days from the date of notice. The Company has asscsscd that no undisclosed income is required to be reported and accordingly, has filled the said returns during the quarter. Subsequently, in the current quarter, the Company and its crtain subsidiarics have received notices under Section 142(1/143(2) of the Income Tax Act, 1961 to funish accounts or documents or information in response thereto for the aforesaid block period for which notices have been issued. The ‘Company is in the process of responding to the said notice. Further, there have been no demands which have been raised on the Company as of date. Based on the foreoing and having regard to the matters of the inquiry during the search and seizure proceedings stated above, while the procecdings are ongoing by the IT Department, the management is of the view that no material adjustments are required to these standalone financial results for the quarter and nine months period ended 31 December 2025 in this regard On 21 November 2025, the Government of India notified the four Labour Codes-namely, the Code on Wages, 2019; the Industrial Relations Code, 2020: the Code on Social Sccurity, 2020; and the Occupational Safety, Health and Working Conditions Code, 2020-thereby consolidating 29 existing labour laws. To facilitate the assessment of the financial impact arising from these regulatory changes, the Ministry of Labour & Employment issued draft Central Rules and related FAQs. ‘The Company has evaluated and disclosed the incremental impact of these changes based on expert input and the best information available, in line with the guidance provided by the Institute of Chartcred Accountants of India. Given the material, regulatory-driven, and non-recurring nature of this impact, the Company has presented the incremental charge relating to gratuity and compensated abscnces, ageregating to € 38 08 million under Exceptionl items'in its standalone unaudited financial results for the quarter and nine months period ended 31 December 2025 The Company continucs to monitor the finalisation of the Central and State Rules and any further government clarifications on other aspeets of the Labour Codes and will record the accounting treatiment as required based on fiture developments. During the quarter ended 31 December 2025, the Company has made an investment in its wholly owned subsidiary, Akums Healtheare Malta Private Limited, by subscribing to 240 equity sharcs of EURO 1 each. Akums Healthcare Malta Private Limited was incorporated on 20 October 2025 to undertake pharmaceutical marketing activities in the European region. The subsidiary is presently in the process of establishing its operational set-up and obtaining regulatory registrations. The said investment is in line with the Company’s stratcgic abjective o expand intermational presence and strengthen its global operations. The Akums Employee Benefit Trust ("ESOP Trust”) has been treated as an extension of the Company and accordingly, shares held by ESOP Trust arc neticd off from the paid up share capital and calculation of eamings per sharc (basic and diluted) have been done accordingly. Furcher, all the assets, liabilities, income and expenses of the ESOP Trust are accounted for as assets, liabilites, income and expenses of the Company. For and on behalf of Board of Dircctors of Akums Drugs and Pharmaceuticals Limited b(',,»fi' i Sanjeev Jain Sandeep Jain Managing Director Managing Director DIN: 00323433 DIN: 00323476, New Delhi 13 February 2026
Page 7
Walker Chandiok & Co LLP Walker Chandiok & Co LLP L 41, Connaught Circus, Outer Circle, New Dethi— 110 001 India T +91 11 45002219 F +91 1142787071 Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) To the Board of Directors of Akums Drugs and Pharmaceuticals Limited 1. We have reviewed the accompanying statement of unaudited consolidated financial results (‘the Statement’) of Akums Drugs and Pharmaceuticals Limited (‘the Holding Company’) and its subsidiaries (the Holding Company and its subsidiaries together referred to as ‘the Group’), (refer Annexure 1 for the list of subsidiaries included in the Statement) for the quarter ended 31 December 2025 and the consolidated year to date results for the period 01 April 2025 to 31 December 2025, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (‘Listing Regulations’). 2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (‘Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 (‘the Act’), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable. Crartered Acoountants Walker Chandiok & Co LLP is registered with imited abilty vath identification edabad, Bengiuns Cranga Cresna Derradun Goa « number AAC-2085 and has its registered da i Pure office at L-41 Connaught Circus. Outer Cucle New Delhi. 110001 India
Page 8
Walker Chandiok & Co LLP Independent Auditor’'s Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont’d) 4. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review reports of the other auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. 5. We draw attention to note 8 to the accompanying Statement relating to a search and seizure operation carried out by the Income Tax Department during the financial year ended 31 March 2025 at certain offices and manufacturing units of the Holding Company and its subsidiaries, and the residences of selected key managerial personnel of the Group from 15 January 2025 to 21 January 2025 under Section 132 of the Income Tax Act, 1961. During the previous quarter, the Holding Company and certain subsidiaries had received notices under Section 158BC of the Income tax Act, 1961, whereby the Holding Company and its certain subsidiaries have complied with the notices by furnishing returns with no undisclosed income for the relevant block period from 01 April 2018 to 12 March 2025. Further, in the current quarter, the Holding Company and its certain subsidiaries have received notices under Section 142(1)/143(2) of the Income Tax Act, 1961 to furnish information for the aforesaid block period. The Holding Company and its certain subsidiaries are in the process of responding to the said notices and submitting the required documents to the Income Tax Department. Pending conclusion of the ongoing search and seizure proceedings, the impact of this matter on the consolidated financial results for the quarter and nine months period ended 31 December 2025 and the adjustments (if any) required is presently not ascertainable Our conclusion is not modified in respect of this matter. 6. We did not review the interim financial information of 7 subsidiaries included in the Statement whose financial information reflects total revenues of ¥ 615.82 million and % 1,618.29 million, total net loss after tax of ¥ 189.91 million and ¥ 646.36 million, total comprehensive loss of ¥ 188.54 million and % 652.50 million, for the quarter and year to date period ended on 31 December 2025, respectively, as considered in the Statement. These interim financial information have been reviewed by other auditor whose review reports have been furnished to us by the management and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the review reports of such other auditor and the procedures performed by us as stated in paragraph 3 above. Further, of these subsidiaries, 1 subsidiary, whose interim financial information has been prepared in accordance with Accounting Standards specified under section 133 of the Act, read with the Companies (Accounting Standards) Rules, 2021 and which has been reviewed by other auditor. The Holding Company’s management has converted the interim financial information of such subsidiary in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015 as applicable to the Company. We have reviewed these conversion adjustments made by the Holding Company’s management. Qur conclusion, in so far as it relates to the balances and affairs of this subsidiary is based on the review report of other auditor and the conversion adjustments prepared by the management of the Holding Company and reviewed by us Our conclusion is not modified in respect of these matters with respect to our reliance on the waork done by and the reports of the other auditor.
Page 9
Walker Chandiok & Co LLP Independent Auditor's Review Report on Consoclidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont’d) 7. The Statement also includes the interim financial information of 3 subsidiaries, which have not been reviewed, whose interim financial information reflects total revenues of % nil and % nil, net loss after tax of % 3.77 million and % 3.77 million, total comprehensive loss of 3.79 million and % 3.79 million for the quarter and year to date period ended 31 December 2025 respectively, as considered in the Statement and have been furnished to us by the Holding Company’s management. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries are based solely on such unreviewed interim financial information. According to the information and explanations given to us by the management, these interim financial information are not material to the Group. Our conclusion is not modified in respect of this matter with respect to our reliance on the financial information certified by the management. For Walker Chandiok & Co LLP Chartered Accountants Firm Registration No: 001076N/N500013 o Tarun Gupta Partner Membership No. 507892 UDIN: 26507842 TuGTKO163 Place: New Delhi Date: 13 February 2026
Page 10
Walker Chandiok & Co LLP Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (Cont’d) Annexure 1 List of subsidiaries included in the Statement Pure and Cure Healthcare Private Limited Malik Lifesciences Private Limited Maxcure Nutravedics Limited Unosource Pharma Limited Akumentis Healthcare Limited Sarvagunaushdhi Private Limited Plenteous Pharmaceuticals Limited Upadhrish Researchem LLP Nicholas Healthcare Limited 10. Akums Healthcare Limited 11. Qualymed Pharma Private Limited 12. Akums Healthcare UK Limited (w.e.f. 18 March 2025) 13. Akums Healthcare Zambia Private Limited (w.e.f. 13 October 2025) 14. Akums Healthcare Malta Private Limited (w.e.f. 20 October 2025) CONOIBWN S Step Down Subsidiary 1. Medibox Pharma Private Limited (subsidiary of Maxcure Nutravedics Limited)
Page 11
Akums Drugs and Pharmaceuticals Lir Regd. Office: 304, Mohan Place, LSC, C-Block, Saraswati Vihar, Delhi-110034 CIN: L24239DL2004PLC125888 Email 1d: cs@akums.net; Website: www.akums.in Statement of unaudited consolidated financial results for the quarter and nine months period ended 31 December 2025 (% in million, unless otherwise stated) Quarter ended Nine months period ended | Year ended S. No.. Particulars 31 December | 30 September [ 31 December | 31 December | 31 December [ 31 March 2025 2025 2024 2025 2024 2025 Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited T [fncome Revenue from operations 11,59587 | 10,175.30 [ 10,1041 3200149 30,626.11| 41,181.58 Other income 34328 323.65 145.61 934.24 345.77 5212 Total income (I) 1193915 1049895 | 10249.72 3294573 | 3097188 | 41,702.80 11 |Expenses Cost of materials consumed 611255 552626 5,645.98 17,1777 16.297.63 [ 22,536.08 [Purchase of stack-in-trade 602.86 567.06 30272 1,380.71 161983 [ 181473 Changes in inventorics of finished goods, stock-in-trade and work-in-progress 36 (167.69) 7523 32.08 2602 (16.47) [Employee benefits cxpense 1,893.79 1,892.70 1,755.98 5,547.92 531924] 715821 Finance cosis (refer nofe 3) 23742 233.04 5134 701.81 300.58 346.00 Depreciation and amortisation expense 396.49 378.64 44520 1,144.33 113449 153446 Fair value changes to financial instruments - - - - (38.67) (38.67) Other expenses 1,447.74 141221 1,110.55 422998 369639 5082.90 Total expenses (IT) 10.761.21 9,842.22 9,387.00 30.154.60 | 28,3551 | 38.417.24 TIT | Profit before exceptional items and tax (1-IT) 1,177.94 656.73 862.72 2,791.13 2,61637 | 3,285.56 IV |Exceptional items (refer notc 7) 1828 - “7.81) 1828 (8430) (166.97)] V| Profit before tax for the period! year (II-IV) 995.66 656.73 910.53 2,608.85 270117 | 345253 VI |Taxexpense Current tax for current period/ year 285.01 19135 205.77 72076 626.86 813.67 for earlier years (15.32) - 18.32) (15.32) (11.30) 16.18) Deferred tax charge/ (credit) for current period! year 35.98 3842 4946 139.61 15451 (794.29) for earlier years 1325 - 1050 1325 (10.61) 1156 Total tax expense 31892 229.77 247.41 858,30 759.46 1476 VI Profit for the period/ year (V-VI) 676.74 42696 663.12 1,75055 194171 | 3437.77 VIII [Other comprehensive income - liems that will not be reclassified to profit and loss 747 (53.72) 248 (23.28) (1.07) (13.62) - income-tax on items that will not be reclassified to profit and loss (©.45) 10.69 ©.79) 467 0.28 267 Other comprehensive income, net of tax 7.02 (43.03) 169 (8.61) (©.79) (10.95)] IX [Total cmprehensive income for the period/ year (VI+VIII) (comprising e p— s L7194 194052 | 342682 profit for the period! year and other comprehensive income, net of fax) X [Profit for the period/ year attributable to: Owners of the Parent 663.17 40783 651.82 1,705.75 190559 | 3,381.76 Non controlling interest 1357 19.13 1130 44.80 36.12 5601 XI |Other comprehensive income for the period/ year attributable to: Owners of the Parent 7.00 (42.95) 182 (18.32) (0:82) (11.03) Non controlling interest 0.02 (0.08) (©.13) (0.29) 0.03 0.08 XII |Total comprehensise income for the period/ year attributable to: Owners of the Parent 67017 364.88 653.64 1,687.43 190477 337073 Non controlling interest 1359 19.05 1117 4 3615 56.00 XTI |Paid-up share capital (net off shares held by ESOP trust) (refer note 4) 30621 30621 306.21 30621 306.21 30621 XIV |Other equity 30,163.93 XV |Earning per share (EPS) (face value of ¥ 2/ each) (in 3)* 433 2.66 426 1114 1284 22.60 Basic and diluted *EPS for the quarters and nine months period have not been annualised
Page 12
UNAUDITED CONSOLIDATED SEGMENT WISE REVENUE, RESULTS, AS! TS AND LIABILITIES The Group is engaged in five business segments a) Contract Development and Manufacturing operations (CDMO); b) Active Pharmaceutical Ingredient (APT); ) Domestic Branded Formulations; d) International Branded Formulations and e) Trade Generics. Disclosures as per Indian Aceounting Standard (Ind AS-108) "Operating Segment" has been disclosed herewith : in million, unless otherwise stated) Quarter ended Nine months period ended | Year ended . 31 December| 30 September | 31 December | 31 December | 31 December Particulars 2025 2 2024 2025 qozs | ¥ Mk Unaudited | _Unaudited | Unaudited | _Unaudited | _Unuudited | _ Audited 1. Revenue from operations (including inter-scgment) 2) CDMO 981558 852666 843041 | 2690398 | 2539485 | 3440242 b) APT 679.51 508.99 477.88 1,777.61 2,105.11 2,771.23 ¢) Domestic branded formulations 1,148.33 1,219.40 1,102.00 344239 3,299.36 4335.88 ) Intemational branded formulations 501.35 2431 42439 107630 1,020.18 142613 ©) Trade goncrics 247.62 24512 30432 72820 947.30 117879 1239239 1072448 | 1075950 | 3401848 | 3277580 | ad,114.45 11. Revenue from operations (external customers) @) CDMO 9,155.93 504329 787442 | 2533258 | 23esLI6| 3207876 b) API 54237 444.60 40056 1,437.30 169152 2,192.96 ¢) Domestic branded formulations 1,148.33 1,219.40 1,102.00 344239 320036 4335.88 4) International branded formuletions 501.35 424.89 1,076.30 1,020.18 1.426.13 o) Trade generics 24789 24370 30224 72292 92489 1,147.85 Revenue from operations 11,595.87 1017530 | 10,104.11] 3201149 | 3062611 4118158 111, Segment results before depreciation* 2) CDMO 1258.32 843.10 1,213.64 3206.04 365231 453892 b) API (73.84) (14031) (108.94) @77.46) (373.39) (38.01) ¢) Domestic branded formulations 25459 26387 203.57 676,93 54376 767.25 d) International branded formulations 12022 54.88 77.90 264.58 188.37 275,91 ©) Trade gencrics (2.15) @8.73) (#360) (115.63) (182.06) @8217) 1V. Segment results** &) CDMO 87970 227463 276245 3,323.83 b) API (210.48) (409.05) (617.67) (757.10) ¢) Domestic branded formulations 19131 660.73 52813 745,74 d) International branded formulations 7356 245,69 17447 25788 ¢) Trade gencrics G5.12) ©1.54) (12631) @o227) (306.33) Sub total LiLT 342,25 364869 264511 3.264.01 Unallocated corporate income/ (expenses) [net] 160 210 580 4497 66,32 Interest income 274.29 54.62 787.17 178.48 237.78 Finance costs @19.12) (625) (65053) ©52.19) (282.56) Profit before exceptional items and tax 117794 636,73 86272 279113 261637 328556 Exceptional items 18228 = @781 18208 (34.80) (166.97) Profit before tax 995.66 5673 91053 2,608.35 270017 34505 Tax expenses 318.92 220.77 24741 858.30 75946 14.76 Profic for the period/ year 7674 42696 663.12 175055 194171 343777 V. Segment assets 2) CDMO 3028573 2701856 | 3028573 | 2791856 [ 2701632 b) APL 429856 437227 4208.56 437227 ¢) Domestic branded formulations 527.01 80386 827.01 503,86 d) International branded formulations 85387 74249 85387 74249 ¢) Trade gencrics 485.23 923,39 48523 92339 Less i Inter-segment climinations 907.99) (845.50) (907.99) (845.50) Scgment asses 3584241 1507 | 3584241 3391507 Un-allocated corporate assets 18,125.90 469764 | 1812590 469764 7,990.20 Total assets 5396831 S51,592.93 | IBGI271| 5396831 | 3861271 dl13442 VI Segment linbilities 2)CDMO 18,791.06 17,289.63 682473 1879106 728097 b) APL 579.05 435.43 351.87 57905 601.48 ¢) Domestic branded formulations 1220.15 1,263.93 122015 1,100.83 ) Tnternational branded formulations 45236 54376 s12.21 ¢) Trade generics 0186 44675 43280 Less i~ Inter-segment climinations (845.50) (907.99) (35.72) Scgment liabilities 357905 | 2067278 919257 Uncallocated corporate fiabilities 83530 898,86 825,47 1,305.74 Total bili 19,908.64 9,478.11 21,498.25 10.498.31 * Segment results before depreciation is calculated as the sum of profit (loss) before tax, exceptional items, finance costs, fair value changes o financial instruments and depreciation and amartisation expense “* Segment results is caleulated as scgment results before depreciation less finance cosis pertaining to segments and depreciation and amortisation expense. -
Page 13
Notes : 1 9 The sbove consolidated financial results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meetings held on |3 February 2026. These consolidated financial results for quarter and nine months ended 31 December 2025 have been subjected to limited review by the statutory auditors of the Holding Company. The limited review report does not contain any qualification. The above consolidated financial results of Akums Drugs and Pharmaceuticals Limited (the 'Holding Company' or ‘Parent), together with its subsidiaries (collectively the ‘Group) have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended and prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (as amended). ‘The Holding Company had completed its Initial Public Offer (IPO) of 27,368,143 cquity shares of face value of ¥ 2 cach at an issu price of ¥ 679 per share (including share premium of 2 677 per share). A discount of % 64 per share was offered o eligible employees biding in the employee reservation portion of 243,826 cquity shares. Pursuant to IPO, the equity shares of the Holding Company were listed on National Stock exchange of Tndia Limited (NSE) and BSE Limited (BSE) on 6 August 2024, The issue comprised of fresh issue of 10,037,708 equity shares aggregating (0 ¥ 6,800.00 million and offer for sale of 17,330,435 cquity shares by selling sharcholders, ageregating to ¥ 11,767.37 million. TPO related expenses were earlier estimated at 2 1,116.58 million and were allocated between the Holding Company and the selling sharcholders in proportion 1o their respective shares in the issuc. Subsequent to quarter ended 31 December 2025, the Holding Company has assessed that the actual IPO expenses amounted to % 990.61 million as against the earlier estimated expenses of 2 1,116.58 million as disclosed in the Prospectus, resulting in an excess provision of % 125.98 million. The IPO expenses were initially withheld from the IPO proceeds were allocated between the Holding Company and the selling sharcholders in proportion to their respective sharcs in the issue. Accordingly, the excess amount of 2 125.98 million is being released proportionately to the Holding Company and the selling shareholders, Out of the aforesaid excess amount, Z 48.10 million attributable to the Holding Company is to be reallocated towards the objects of the issuc as decided by the Board. The balance amount aitributable to the selling sharcholders will be relcased to them in proportion to their respective entitlements. The utilisation of the net PO proceeds, prior o aforementioned reallocation, is summarised below: Planned net | Actualnet | Utilisation upto| Unutilised proceedsas | proceeds | 31 December | amount as on 31 Objects per 2005 | December 2025 prospectus Repayment/prepayment of all or certain barrowings of Holding Company 1,595.10 1,599.10 1599.10 - Repayment/prepayment of all or certain borrowings of subsidiarics namely, 22 .9 2.270. - Maxcure Nutravedics Limited and Pure and Cure Healtheare Private Limited R 227050 2100 [Funding incremental working capital requirements of Holding Company 550.00 55000 550.00 - [Pursuing inorganic growth initiatives through acquisitions 278.70 278.70 278.70 - General corporate purposes 1,675.00 1,675.00 1,675.00 - Total proceeds (net of IPO expenses) 6,373.70 637370 6,373.70 - The Akums Employce Benefit Trust ("ESOP Trust") has been treated as an extension of the Holding Company and accordingly, shares held by ESOP Trust are netied off from the paid up share capital and calculation of carnings per share (basic and diluted) have been done accordingly. Further, all the assets, liabilities, income and expenses of the irust are accounted for as assets, liabilities, income and expenses of the Holding Company. During the nine months period ended 31 December 2025, one of the group company has reccived an advance from a customer towards product development and manufacturing services to be rendered till December 2032. In accordance with Ind AS 115 ‘Revenue from Contracts with Customers’, the advance has been recognised as a contract liability, Given the significant time period between receipt of the advance and the expected delivery of performance obligations, the Group company has assessed this arrangement (o contain a significant financing component, Accordingly, a notional interest expense of ¥ 197.14 million for the quarter ended 31 December 2025 and % 578.79 million for the nine months period ended 31 December 2025 has been recognised in these consolidated financial resulis, representing the unwinding of the contract liability. Further, in accordance with Ind AS 12 Income Taxes, a deferred tax asset of Z 49.62 million for the quarter ended 31 December 2025 and 2 145.67 million for the nine months period ended 31 December 2025 has been recognised on the notional interest expense in these consolidated financial results. During the quarter ended 31 December 2025, the Holding Company has made an investment in its wholly owned subsidiary, Akums Healthcare Malta Privatc Limited, by subscribing to 240 equity shares of EURO 1 cach. Akums Healthcare Mlta Private Limited was incorporated on 20 October 2025 to undertake pharmaceutical marketing activities in the European region, The subsidiary is presently in the process of establishing its operational sct-up and obtaining regulatory registrations. The said investment is in line with the Group strategic objective to expand its international presence and strengihen iis global operations. On 21 November 2025, the Government of India notified the four Labour Codes-namely, the Code on Wages. 2019: the Industrial Relations Cade. 2020. the Code on Social Security, 2020; and the Occupational Safety, Health and Working Conditions Code, 2020-thereby consolidating 29 existing labour laws. To facilitate the assessment or the financial impact arising from these regulatory changes, the Ministry of Labour & Employment issucd drafi Central Rules and related FAQs. ‘The Group has evaluated and disclosed the incremental impact of these changes based on expert input and the best information available, in line with the guidance provided by the Institute of Chartered Accountants of India. Given the material, regulatory-driven, and non-recurring nature of this impact, the Group has presented the incremental charge relating to gratuity and compensated absences, ageregating to ¥ 182.28 millions under Exceptional items' in its consolidated unaudited financial results for the quarter and nine months ended 31 December 2025, The Group continues to monitor the finalisation of the Central and State Rules and any further government clarifications on ather aspects of the Labour Codes and will record the accounting treatment as required based on future developments
Page 14
During the financial year cnded 31 March 2025, from 15 January 2025 to 21 January 2025, the Income Tax Depariment ('IT Depertment”) has conducted a search and scizure operation under Section 132 of the Income Tax Act, 1961, at certain offices and manufacturing units of the Holding Company and its certain subsidiaries, and the residences of select key managerial personnel of the Group. During the scarch and seizure proceedings, the Group has fully cooperated, provided the required information and responses to the IT Department. As a part of scarch and seizure operation, the IT Department has cloned electronic books of accounts, laptops, data backups and seized certain documents, cash and other materials for further investigation. The business and operations of the Group continued without any disruptions, except some minor operational hiceups, and customer commitments were met during this period. During the previous quarter, the Holding Company and its certain subsidiaries has received notices under Seetion 158BC of the Income tax. Act, 1961, which requires the Holding Company and its certain subsidiaries, in consequence of aforesaid scarch and seizure operations initiated under Section 132, to furnish returns of undisclosed income for the relevant block period from 01 April 2015 to 12 March 2025 in the preseribed form and manner as per rule 12AE of Income-tax Rules, 1962 setting forth such other particulars as may be prescribed by the Income-tax Act, 1961 within 60 days from the date of notice. The Holding Company and its certain subsidiaries have assessed that no undisclosed income is required to be reported and accordingly, have filled the said returns during the quarter. Subsequently, in the current quarter, the Holding Company and its certain subsidiaries have reccived notices under Section 142(1)/143(2) of the Income Tax Act, 1961 to furnish accounts or documents or information in response thereto for the aforesaid block period for which notices have been issued. The Holding Company and its certain subsidiaries are in the process of responding to the said notices Further, there have been no demands which have been raised on the Group as of date. Based an the foregoing and having regard 10 the matters of the inquiry during the search and seizure proceedings stated above, while the proceedings are ongoing by the IT Department, the management is of the view that no material adjustments are required to these consolidated financial results for the auarter and nine months neriod ended 31 December 2025 in this revard For and on behalf of Board of Directars of Akums Drugs and Pharmaceuticals Limited Sanjeev Jain Sandeep Jain Place: New Delhi Managing Director Managing Director Date: 13 February 2026 DIN: 00323433 DIN: 00323475
Page 15
DRUGS & PHARMACEUTICALS LTD. @ Plot No. 13! LoldB Block- C. Mango\pun Ind. Areq, Phase~l, @ www.akums.in (Adjoining CBSE Office)Delhi ~ 10083 (INDIA). [ akumsho@akums.net u m g ©) +91-11-69041000 CIN: L24239DL2004PLC 125888 4T3 +91-11-27023256 Statement of Deviation / Variation in utilisation of funds Raised Name of listed entity Akums Drugs and Pharmaceuticals Limited Mode of Fund Raising Public Issues August 2, 2024 Date of Raising Funds (Listed on August 6, 2024 on BSE Limited and National Stock Exchange of India Limited) Amount Raised 6800.00 million Report filed for Quarter ended 31-12-2025 Monitoring Agency Applicable e i Aaency Naiie, It CRISIL Ratings Limited Is there a Deviation / Variation in use of funds raised If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders If Yes, Date of shareholder Approval | Not Applicable Explanation for the Deviation / Variation Comments of the Audit Committee after review Comments of the auditors, if any No Comments Objects for which funds have been raised and where there has been a deviation, in the following table No Not Applicable Not Applicable No Comments Amount of Modified Original Modified Deviation/Variatio Object, if Allocatio | allocatio Fu_n‘ds n for the quarter R(_smark 5 Utilised 3 s if any any n n, if any according to applicable object Repayment/ prepayment of Not ~ indebtedness of the Company Applicable 15910 0 159910 | 0 Repayment/ prepayment of indebtedness of its Subsidiaries Not namely, Maxcure Nutravedics Limited Avplicabi 2,270.90 0 2,270.90 | 0 = and Pure and Cure Healthcare Private | *PPIP1 Limited Fum%mg incremental working capital | Not - 550.00 0 55000 | 0 R requirements of our Company Applicable Pursuing inorganic growth initiatives Not through acquisitions Applicable 278.70 0 27870 | 0 = Not - = General corporate purposes (GCP) Applicable 1,675.00 0 1,675.00 | 0 Total 6,373.70** 6,373.70 Registered Office © 304, Mohan Flace, LS.C, Block-C, Saraswati Vinar, New Delhi-110034 (NDIA) & +91-1-47511000 . +91-11-27023256
Page 16
AKUMS DRUGS & PHARMACEUTICALS LTD. @ Plot No. 131 to 133, Block-C, Mangolpuri Ind. Areq, Phase-1, @ www.akums.in (Adjoining CBSE Office) Delhi - 110083 (INDIA). & akumsho@akums net u m S © +91-1-69041000 CIN: L24239DL2004PLC 125888 453 +81-11-27023256 T *The amount utilized for general corporate purposes does not exceed 25% of the Gross Proceeds (amounting to Rs 1700.00 million) from the Fresh Issue. ** The amount of original allocation represents the amount raised through fresh Issue net of offer expenses as mentioned in the prospectus dated August 1, 2024. Deviation or variation could mean: (a) Deviation in the objects or purposes for which the funds have been raised or Chief Financial Officer Date: 13.02.2026 Place: Delhi Registered Office. © 304, Mohan Flace, LS C, Block-C, Saraswati Vihar, New Delhi-110034 (INDIA) & +91-11-47511000 4 Q111427023256